On Wednesday, medtech giant Abbott announced that its new leadless pacemaker system, Aveir DR, has been approved by the FDA. This is the first time the FDA has given a thumbs up to a device of this ...
NEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to ...
Once both of the leadless pacemakers are in place, Abbott's i2i technology uses high-frequency pulses to send beat-to-beat information through the blood between the pair of devices, allowing them to ...
Abbott’s Aveir DR system links two pacemakers that are implanted in the right ventricle and right atrium. The devices work together using what Abbott has dubbed its implant-to-implant, or i2i, ...
Abbott ABT announced a favorable outcome on its leadless pacemaker. The company unveiled late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study. The ...
This story is part of a series on the current progression in Regenerative Medicine. This piece discusses the regeneration of the cardiovascular system. In 1999, I defined regenerative medicine as the ...
Abbott (ABT Quick Quote ABT - Free Report) recently received a CE Mark in Europe for the AVEIR dual chamber (DR) leadless pacemaker system, the first ever dual chamber leadless pacemaker that treats ...
Leadless cardiac electrophysiology devices have been around for a while now, but Abbott Laboratories of Abbott Park, Ill., has managed to beat the competition in the market for dual chamber pacing via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results